Physician profile
Daniela Russi
NPI 1548502701
$11,046.96
in general payments reported to CMS, 2019-2025
12 companies · $946 in 2025
The $946 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $47.69 · 2021: $175 · 2022: $3,172 · 2023: $4,962 · 2024: $1,520 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,214 · Food and Beverage: $1,439 · Honoraria: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,213.56 |
| Food and Beverage | $1,438.92 |
| Honoraria | $775.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pierre Fabre Pharmaceuticals, INC. | $9,428.84 | 2021-2025 | Hemangeol |
| Chiesi USA, INC. | $923.23 | 2024-2025 | Filsuvez |
| Pfizer INC. | $170.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $168.76 | 2019-2020 | |
| Abbvie INC. | $133.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $67.19 | 2021-2025 | |
| Krystal Biotech INC | $32.83 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $29.82 | 2023 | Ycanth |
| Leo Pharma INC. | $27.07 | 2024 | Adbry |
| Incyte Corporation | $25.37 | 2021 | |
| Lnhc, INC | $19.98 | 2025 | Zelsuvmi |
| Genzyme Corporation | $19.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Russi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.